EQ

Equillium Inc

EQ, USA

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

https://www.equilliumbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EQ
stock
EQ

Insider Sale: Sr. Vice President and COO of $EQ Sells 11,900 Shares Quiver Quantitative

Read more →
EQ
stock
EQ

Chip Stocks Meet Harvard’s Criteria for a Bubble: Equity Insight Bloomberg.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$2.5

Analyst Picks

Strong Buy

0

Buy

0

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.48

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.26 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.12

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 16.87% of the total shares of Equillium Inc

1.

Decheng Capital LLC

(7.4741%)

since

2025/06/30

2.

Takeda Pharmaceutical Co Ltd

(3.067%)

since

2025/06/30

3.

Vanguard Group Inc

(1.385%)

since

2025/06/30

4.

Cota Capital Management, LLC

(0.945%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(0.9388%)

since

2025/07/31

6.

Renaissance Technologies Corp

(0.4606%)

since

2025/06/30

7.

abrdn Life Sciences Investors

(0.3801%)

since

2025/08/31

8.

Geode Capital Management, LLC

(0.3295%)

since

2025/06/30

9.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2857%)

since

2025/07/31

10.

Citadel Advisors Llc

(0.2197%)

since

2025/06/30

11.

Callan Capital, LLC

(0.1675%)

since

2025/03/31

12.

Fidelity Extended Market Index

(0.1666%)

since

2025/07/31

13.

UBS Group AG

(0.1404%)

since

2025/06/30

14.

State Street Corp

(0.1004%)

since

2025/06/30

15.

AlphaCore Capital LLC

(0.088%)

since

2025/06/30

16.

Prudential Financial Inc

(0.0659%)

since

2025/06/30

17.

PGIM Quantitative Solutions US Micro Cap

(0.0659%)

since

2025/06/30

18.

Fidelity Total Market Index

(0.0592%)

since

2025/07/31

19.

Northern Trust Corp

(0.0589%)

since

2025/06/30

20.

Commonwealth Equity Services Inc

(0.042%)

since

2025/06/30

21.

Fidelity Series Total Market Index

(0.0413%)

since

2025/07/31

22.

Baader Bank INC

(0.0398%)

since

2025/06/30

23.

Spartan Extended Market Index Pool F

(0.0313%)

since

2025/07/31

24.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.03%)

since

2024/12/31

25.

NT Ext Equity Mkt Idx Fd - NL

(0.0284%)

since

2025/06/30

26.

Ground Swell Capital, LLC

(0.0278%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - L

(0.0275%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0275%)

since

2025/06/30

29.

Susquehanna International Group, LLP

(0.0254%)

since

2025/06/30

30.

Apollon Wealth Management, LLC

(0.0233%)

since

2025/06/30

31.

TRITONPOINT WEALTH LLC

(0.0227%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.022%)

since

2025/06/30

33.

Virtu Financial LLC

(0.0171%)

since

2025/06/30

34.

Fidelity Nasdaq Composite Index

(0.0158%)

since

2025/07/31

35.

Spartan Total Market Index Pool G

(0.0152%)

since

2025/07/31

36.

Vanguard U.S. Eq Idx £ Acc

(0.0098%)

since

2025/07/31

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0078%)

since

2025/06/30

38.

State St US Extended Mkt Indx NL Cl C

(0.0069%)

since

2025/08/31

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0066%)

since

2024/12/31

40.

State St US Ttl Mkt Indx NL Cl A

(0.0035%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.06

EPS Estimate

-0.22

EPS Difference

0.16

Surprise Percent

72.7273%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.